<![CDATA[Osteoarthritis (OA) is a chronic degenerative disease that affects the joints, especially heavy joints such as the knees and hips. OA often causes chronic pain and limited mobility, which is even more complex when accompanied by comorbid hypertension and type 2 diabetes mellitus. These comorbidities increase the risk of pharmacotherapy side effects and drug interactions, requiring a multidisciplinary approach and careful clinical pharmacy monitoring. The purpose of this report is to review the pharmacotherapy management of grade 4 OA Hip Dextra with comorbid HT and DMT2, assessing the safety, effectiveness, and role of clinical pharmacists in therapy optimization. A retrospective case study was conducted by analyzing the patient's medical records, including anamnesis, physical examination, laboratory, pharmacological therapy, and clinical response. The analysis was conducted based on the national guidelines of the Indonesian Ministry of Health, the 2021 National Formulary, PERKENI 2023, and PAPDI 2021. The patient was given combination therapy of NSAIDs, analgesics, prophylactic antibiotics, muscle relaxants, gastric protection, and supplementation for anemia. Therapeutic adjustments were made according to the patient's response and laboratory parameters. Clinical pharmacy monitoring ensures pain control, mobility, hemoglobin, and blood sugar. A multidisciplinary approach based on national guidelines has been shown to improve the safety and effectiveness of OA therapy with multiple comorbidities.]]>
